Optimum dosage regimen of palivizumab?

Palivizumab is a humanized, monoclonal antibody used to protect ut-risk infants against respiratory syncytial virus (RSV) infection. The regular dosage Scheme causes a low initial trough level and accumulation of the antibody after subsequent injections. Using a simple pharmacokinetic model, the authors devised an alternative dosage regimen that might correct these problems while cutting costs by 35%. To spare health care budgets, dosage schemes for future monoclonal antibodies must be chosen carefully.